There is consensus on the safety of standard dose direct oral anticoagulants (DOACs) for stroke prevention in patients undergoing cardioversion of atrial fibrillation (AF), but outcomes of reduced dose DOACs in this setting remain unclear.

There have been limited data examining the temporal relationship between device-derived daily activity and ventricular arrhythmias (VAs).

In patients with unexplained syncope, an implantable cardiac monitor (ICM) is an effective tool to guide treatment decisions.1 If the ICM detects an arrhythmia associated with symptoms, implantation o...